The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

"The launch of PeachesRx is the natural next step in Mangoceuticals’ expansion as we continue to redefine direct-to-consumer healthcare solutions," said Jacob Cohen, CEO and Founder of Mangoceuticals, ...

Net Income was $75.6 million, up from a loss of $ ... on the shortage list, and these are compounded versions of Ozempic and Wegovy. Hims & Hers Plans to Bring Generic GLP-1 to Market in 2025 ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have documented vision problems while people are taking GLP-1 medications.

weight loss medications are often top of mind. A Google Trends study published in the National Library of Medicine found a significant and growing public interest in GLP-1 agonists between 2023 ...

Weight loss medications, classified as GLP-1 agonists, stimulate a naturally occurring hormone called GLP-1, which stands for glucagon-like peptide 1. That hormone has several roles, such as ...